| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 02/06/2003 | WO2003010297A1 Probiotic bifidobacterium strains |
| 02/06/2003 | WO2003010281A2 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
| 02/06/2003 | WO2003010168A1 4-oxoimidazolidine-2-spiropiperidine derivative |
| 02/06/2003 | WO2003010160A2 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists |
| 02/06/2003 | WO2003010147A1 Acidic quinolone derivatives |
| 02/06/2003 | WO2003010131A1 Alpha-ketoglutarates of active ingredients and compositions containing same |
| 02/06/2003 | WO2003009833A1 Sustained release delivery system |
| 02/06/2003 | WO2003009815A2 Compositions and methods for modulating blood-brain barrier transport |
| 02/06/2003 | WO2003009779A2 Delivery of therapeutic capable agents |
| 02/06/2003 | WO2003009778A2 Methods and devices for delivery of therapeutic capable agents with variable release profile |
| 02/06/2003 | WO2003009777A2 Delivery of therapeutic capable agents |
| 02/06/2003 | WO2003000256A9 Substituted oxazolidinones for combinational therapy |
| 02/06/2003 | WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/06/2003 | WO2002070001A3 Use of lp82 to treat hematopoietic disorders |
| 02/06/2003 | WO2002067851A3 Method for treating fibrotic diseases or other indications iiic |
| 02/06/2003 | WO2002066418A3 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor |
| 02/06/2003 | WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof |
| 02/06/2003 | WO2002061110A3 Nucleic acid derivatives |
| 02/06/2003 | WO2002030470A9 Methods and compositions for nucleic acid delivery |
| 02/06/2003 | WO2002020722A3 Methods and compositions for in vitro targeting |
| 02/06/2003 | WO2002019963A3 Synthetic erythropoiesis stimulating proteins |
| 02/06/2003 | WO2002002645A8 COLD WATER SOLUBLE β-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 02/06/2003 | WO2002002095A3 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin |
| 02/06/2003 | WO2001066139A9 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 02/06/2003 | WO2001064911A9 18232, a dual specificity phosphatase |
| 02/06/2003 | WO2001047946A3 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 02/06/2003 | US20030028008 Nucleotide sequences coding polypeptide for use in the treatment of urogenital, tumor, antherosclerotic and kidney disorders |
| 02/06/2003 | US20030028004 68730 and 69112, protein kinase molecules and uses therefor |
| 02/06/2003 | US20030027999 143 human secreted proteins |
| 02/06/2003 | US20030027983 Transport protein for use in the treatment of blood, hypertensive and epileptic disorders |
| 02/06/2003 | US20030027867 Use of R-NSAID compounds for anti-HIV treatment |
| 02/06/2003 | US20030027852 Substituted pyrrolidine-2,3,4-trione 3-oxime deerivatives which are active as NMDA receptor antagonists |
| 02/06/2003 | US20030027828 Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation, and their use |
| 02/06/2003 | US20030027820 Method for treating fibrotic diseases or other indications V |
| 02/06/2003 | US20030027337 Sequence-specific DNA recombination in eukaryotic cells |
| 02/06/2003 | US20030027299 Biochemical conjugate for use in the treatment or prevention of stroke, heart defect, veinous thrombosis, sepsis and embolism |
| 02/06/2003 | US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides |
| 02/06/2003 | CA2455602A1 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
| 02/06/2003 | CA2454803A1 Probiotic bifidobacterium strains |
| 02/06/2003 | CA2450073A1 Compositions and methods for modulating blood-brain barrier transport |
| 02/05/2003 | EP1281401A2 The medical effect of Jojoba oil |
| 02/05/2003 | EP1281392A1 Cosmetic or/and pharmaceutical compositions containing plant extracts |
| 02/05/2003 | EP1281325A1 Nutritional composition preventing bacterial overgrowth |
| 02/05/2003 | EP1280909A2 Human lipocalin homologs and polynucleotides encoding the same |
| 02/05/2003 | EP1280820A2 Anti-inflammatory compounds and uses thereof |
| 02/05/2003 | EP1280815A1 29 human secreted proteins |
| 02/05/2003 | EP1280805A1 Novel imidazotriazinones and the use thereof |
| 02/05/2003 | EP1280799A1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 02/05/2003 | EP1280776A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis |
| 02/05/2003 | EP1280774A1 Substituted indoles as parp inhibitors |
| 02/05/2003 | EP1280758A1 Gallic acid derivatives and use for exploring endogenetic coagulation |
| 02/05/2003 | EP1280572A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280570A2 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280569A1 Delivery systems for treatment of vascular disease |
| 02/05/2003 | EP1280568A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280567A2 Nitric oxide-releasing metallic medical devices |
| 02/05/2003 | EP1280555A2 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist |
| 02/05/2003 | EP1280548A2 Subcutaneous administration of cagulation factor vii |
| 02/05/2003 | EP1280540A1 Modified factor viii |
| 02/05/2003 | EP1280533A2 Aldosterone antagonist composition for release during aldosterone acrophase |
| 02/05/2003 | EP1280512A2 Delivery systems for treatment of vascular disease |
| 02/05/2003 | EP1280409A1 A gene therapy system and method using alpha-msh and its derivatives |
| 02/05/2003 | CN1395574A Food product and producing method |
| 02/05/2003 | CN1394855A Substituted heterocyclic compound |
| 02/05/2003 | CN1394604A Indapamide slowly-releasing tablet |
| 02/05/2003 | CN1394597A Process for preparing powder preparation |
| 02/05/2003 | CN1100785C 1,3,4,5-tetrahydrobenzo [c] azepin-3-one disulfide derivative and method |
| 02/05/2003 | CN1100748C Inhibition of matrix metalloproteases by 2-substituted-4-(4-substituted phenyl)-4-oxobutyric acids |
| 02/04/2003 | US6515173 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 02/04/2003 | US6515011 Anticoagulants |
| 02/04/2003 | US6515004 Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease |
| 02/04/2003 | US6514985 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties |
| 02/04/2003 | US6514978 Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants |
| 02/04/2003 | US6514964 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors |
| 02/04/2003 | US6514960 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 02/04/2003 | US6514940 Protected during pasteurization stabilizers (monosaccharides, disaccharides, and oligosaccharides; or amino acids) |
| 02/04/2003 | US6514761 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases |
| 02/03/2003 | WO2002016312A2 Novel compounds inhibiting factor xa activity |
| 02/03/2003 | CA2418283A1 Novel compounds inhibiting factor xa activity |
| 01/30/2003 | WO2003008454A2 Glycoprotein vi fusion proteins |
| 01/30/2003 | WO2003008420A1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]naphthalenyl derivatives with antipsychotic activity |
| 01/30/2003 | WO2003008418A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 01/30/2003 | WO2003008410A2 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 01/30/2003 | WO2003008399A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
| 01/30/2003 | WO2003008392A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 01/30/2003 | WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 01/30/2003 | WO2003008380A1 Carboxylic acid derivatives |
| 01/30/2003 | WO2003008377A1 Prostaglandin analogues_as ep4 receptor agonists |
| 01/30/2003 | WO2003008374A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | WO2003008370A1 Substituted 4-aminocyclohexanols |
| 01/30/2003 | WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 01/30/2003 | WO2003007983A1 Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
| 01/30/2003 | WO2003007970A2 Use of magnesium for preventing in-stent thrombosis and complications after arterial angioplasty with stent placement |
| 01/30/2003 | WO2003007954A2 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | WO2003007942A1 Substituted isoindoles and the use thereof |
| 01/30/2003 | WO2003007933A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
| 01/30/2003 | WO2003007930A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | WO2003007888A2 Fat accumulation-modulating compounds |
| 01/30/2003 | WO2003007873A2 Plasma protein matrices and methods for their preparation |